Pattern and Outcomes of Chest Diseases

Chest--Diseases Clinical Trial

Official title:

Pattern and Outcome of Respiratory Diseases in Patients Admitted in the Chest Department at Assiut University Hospital

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06053528
• Other study ID #: Pattern of chest diseases
• Status: Not yet recruiting
• Start date: October 1, 2023
• Est. completion date: December 1, 2024

Study information

• Verified date: September 2023
• Source: Assiut University
• Contact: Fatma Hamdan Zaki, Resident doctor
• Phone: 01068769640
• Email: fhamdan714[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this study is to determine the pattern and outcome of respiratory diseases in adults patients admitted to the Department of Chest Diseases at Assiut University Hospital.

Description:

Respiratory diseases constitute an important global health burden. Pneumonia, tuberculosis, obstructive and restrictive lung diseases, pleural diseases, and malignancies are common respiratory conditions for hospital admission.Before the emergence of COVID-19, pneumonia, including community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP)/ventilation-associated pneumonia (VAP), was one of the most common infectious diseases, and could cause major health problems, associated with high morbidity and mortality in all age groups worldwide . The outbreak of COVID-19 has significantly changed the epidemiology of respiratory tract infection. More than 376 million people have been infected and 5 million have died in the whole world. This in addition to the long term post COVID pulmonary sequelae. Chronic obstructive pulmonary disease (COPD), lower respiratory tract infections, lung cancer and tuberculosis have been identified as top four respiratory diseases among ten leading causes of death worldwide. The forum of international respiratory societies (FIRS) estimated that 65 million people have moderate to severe COPD resulting in 3 million deaths per year, making it third leading cause of death worldwide .Currently, asthma affects an estimated 334 million people worldwide and is projected to increase to 400 million by the year 2025 .

In ;2015 10,4million people developed TB with 1.4 million global deaths were reported.

Neoplasms of the lungs are the leading cause of cancer incidence and mortality worldwide.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 2000
• Est. completion date: December 1, 2024
• Est. primary completion date: October 1, 2024
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• All adults patients admitted to the Chest Department during the study period will be included.

Exclusion Criteria:

• Patients who will die, be discharged, or be transferred before completing data collection will be excluded from our study.

Related Conditions & MeSH terms

• Chest--Diseases

Intervention

Drug:
• Antibiotic
Effect if treatment

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine number of patients who experience improvement on discharge		One year
Primary	Number of patient who Transferred to another hospital forcontintreatment		One year
Primary	Number of patient died while on admission		One year
Primary	Number of patient who Discharged against medical advice		One year

External Links

•   Global Asthma Report [Internet]. Auckland: Global Asthma Network; 2014. Available from